JP2021519262A5 - - Google Patents
Info
- Publication number
- JP2021519262A5 JP2021519262A5 JP2020551269A JP2020551269A JP2021519262A5 JP 2021519262 A5 JP2021519262 A5 JP 2021519262A5 JP 2020551269 A JP2020551269 A JP 2020551269A JP 2020551269 A JP2020551269 A JP 2020551269A JP 2021519262 A5 JP2021519262 A5 JP 2021519262A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- use according
- indole
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1850380 | 2018-04-05 | ||
| SE1850380-5 | 2018-04-05 | ||
| PCT/SE2019/050312 WO2019194738A1 (en) | 2018-04-05 | 2019-04-04 | Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519262A JP2021519262A (ja) | 2021-08-10 |
| JP2021519262A5 true JP2021519262A5 (enExample) | 2022-04-07 |
| JP7372253B2 JP7372253B2 (ja) | 2023-10-31 |
Family
ID=68101552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551269A Active JP7372253B2 (ja) | 2018-04-05 | 2019-04-04 | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11590130B2 (enExample) |
| EP (1) | EP3773592B1 (enExample) |
| JP (1) | JP7372253B2 (enExample) |
| CN (1) | CN111936143A (enExample) |
| CA (1) | CA3095709A1 (enExample) |
| WO (1) | WO2019194738A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016229294B2 (en) | 2015-03-06 | 2021-11-04 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
| KR20180105685A (ko) | 2016-02-08 | 2018-09-28 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 투카레솔 또는 이의 유사체를 함유하는 조성물 |
| JP7025416B2 (ja) | 2016-06-06 | 2022-02-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 好中球減少症を低減させるための組成物および方法 |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| JP2023524530A (ja) * | 2020-05-04 | 2023-06-12 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法 |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN121127241A (zh) * | 2023-03-10 | 2025-12-12 | 万春药业公司 | 肿瘤联合治疗及使用方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1976515A2 (en) | 2006-01-17 | 2008-10-08 | Abbott Laboratories | Combination therapy with parp inhibitors |
| US20100249112A1 (en) | 2007-05-25 | 2010-09-30 | Astrazeneca R&D | Combination of chk and parp inhibitors for the treatment of cancers |
| EP2217244A4 (en) | 2007-11-12 | 2011-08-31 | Bipar Sciences Inc | TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES |
| RU2010128107A (ru) | 2007-12-07 | 2012-01-20 | Байпар Сайенсиз, Инк. (Us) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp |
| CN101981013B (zh) | 2008-03-27 | 2013-05-29 | 詹森药业有限公司 | 作为parp和微管蛋白聚合抑制剂的四氢菲啶酮和四氢环戊二烯并喹啉酮 |
| ES2367760T3 (es) | 2008-03-27 | 2011-11-08 | Janssen Pharmaceutica, N.V. | Derivados de quinazolinona como inhibidores de la polimerización de la tubulina. |
| CN102307475A (zh) | 2009-02-04 | 2012-01-04 | 彼帕科学公司 | 用与生长因子抑制剂组合的parp抑制剂治疗肺癌 |
| EP2459561A1 (en) | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| EP2576514A1 (en) * | 2010-06-04 | 2013-04-10 | Exonhit Sa | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
| DK2688883T3 (en) | 2011-03-24 | 2016-09-05 | Noviga Res Ab | pyrimidine |
| TWI577693B (zh) | 2011-05-31 | 2017-04-11 | 江蘇康緣藥業股份有限公司 | 聚（ａｄｐ-核糖）聚合酶之三環抑制劑 |
| US9132120B1 (en) | 2012-04-02 | 2015-09-15 | Stc.Unm | Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers |
| JP6615746B2 (ja) | 2013-04-09 | 2019-12-04 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 腫瘍選択的併用療法 |
| US10195175B2 (en) * | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| WO2017013593A1 (en) | 2015-07-22 | 2017-01-26 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| EP3380454A4 (en) | 2015-11-20 | 2019-04-03 | Lee, Hoyun | CHINOLINE-CHALCON COMPOUNDS AND USES THEREOF |
| WO2017223516A1 (en) | 2016-06-24 | 2017-12-28 | The Regents Of The University Of California | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
-
2019
- 2019-04-04 WO PCT/SE2019/050312 patent/WO2019194738A1/en not_active Ceased
- 2019-04-04 CA CA3095709A patent/CA3095709A1/en active Pending
- 2019-04-04 US US16/981,232 patent/US11590130B2/en active Active
- 2019-04-04 CN CN201980024687.3A patent/CN111936143A/zh active Pending
- 2019-04-04 EP EP19781419.7A patent/EP3773592B1/en active Active
- 2019-04-04 JP JP2020551269A patent/JP7372253B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519262A5 (enExample) | ||
| JP2013505249A5 (enExample) | ||
| JP2024530495A5 (enExample) | ||
| JP2010528026A5 (enExample) | ||
| ES2670864T3 (es) | Inhibidores de histonas desmetilasas | |
| JP2015232006A5 (enExample) | ||
| RU2013128612A (ru) | Соли и кристаллические формы индуцирующего апоптоз агента | |
| JP2023539715A5 (enExample) | ||
| JP2017516784A5 (enExample) | ||
| JP2007511504A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| HRP20171902T1 (hr) | Farmaceutski oblik za doziranje za oralnu primjenu inhibitora iz obitelji bcl-2 | |
| JP2013544804A5 (enExample) | ||
| JP2011527334A5 (enExample) | ||
| RU2012115851A (ru) | Кристаллические формы и сольваты авт-263 для применения в лечении заболеваний, связанных с белком bcl-2 | |
| JP2023545096A5 (enExample) | ||
| JP2015509540A5 (enExample) | ||
| JP2020504716A5 (enExample) | ||
| JP2021534158A5 (enExample) | ||
| JP2008528671A5 (enExample) | ||
| JP2014514317A5 (enExample) | ||
| JP2009541223A5 (enExample) | ||
| RU2011148521A (ru) | Соль авт-263 и ее формы в твердом состоянии | |
| JP2012520321A5 (enExample) | ||
| JP2010527984A5 (enExample) |